Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Ritchie

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1991
The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. I. Acute effects on HPA axis activity and corticotropin-releasing factor-containing neurons in the rat brainM J Owens, D L Knight, J C Ritchie, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1991
The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administrationM J Owens, D L Knight, J C Ritchie, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 1, 1996
Use of site-specified tritium labelling to confirm the formation of 17-oxosparteine as a minor urinary metabolite of sparteine in manJ C Ritchie, S C Mitchell, R L Smith, et al.
Health Physics|January 1, 1972
Fallout 137 Cs in reservoir sedimentJ C Ritchie, J R McHenry, A C Gill, et al.
Biological Psychiatry|October 1, 1996
Do glucocorticoids contribute to the abnormalities in serotonin transporter expression and function seen in depression? An animal modelT A Slotkin, E C McCook, J C Ritchie, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 1998
Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regionsJ M Radke, M J Owens, J C Ritchie, et al.
Journal of Medicinal Chemistry|November 1, 1991
Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostereA Krohn, S Redshaw, J C Ritchie, et al.
The Journal of Laboratory and Clinical Medicine|May 1, 1970
Regulation of collagen and hyaluronate formation in human synovial fibroblast culturesC W Castor, K Rowe, E L Dorstewitz, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patientsS K Gupta, J C Ritchie, E H Ellinwood, et al.
Archives of General Psychiatry|May 1, 1985
Plasma cortisol determination for the dexamethasone suppression test. Comparison of competitive protein-binding and commercial radioimmunoassay methodsJ C Ritchie, B J Carroll, P R Olton, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1991
The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. I. Acute effects on HPA axis activity and corticotropin-releasing factor-containing neurons in the rat brainM J Owens, D L Knight, J C Ritchie, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1991
The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administrationM J Owens, D L Knight, J C Ritchie, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 1, 1996
Use of site-specified tritium labelling to confirm the formation of 17-oxosparteine as a minor urinary metabolite of sparteine in manJ C Ritchie, S C Mitchell, R L Smith, et al.
Health Physics|January 1, 1972
Fallout 137 Cs in reservoir sedimentJ C Ritchie, J R McHenry, A C Gill, et al.
Biological Psychiatry|October 1, 1996
Do glucocorticoids contribute to the abnormalities in serotonin transporter expression and function seen in depression? An animal modelT A Slotkin, E C McCook, J C Ritchie, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 1998
Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regionsJ M Radke, M J Owens, J C Ritchie, et al.
Journal of Medicinal Chemistry|November 1, 1991
Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostereA Krohn, S Redshaw, J C Ritchie, et al.
The Journal of Laboratory and Clinical Medicine|May 1, 1970
Regulation of collagen and hyaluronate formation in human synovial fibroblast culturesC W Castor, K Rowe, E L Dorstewitz, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patientsS K Gupta, J C Ritchie, E H Ellinwood, et al.
Archives of General Psychiatry|May 1, 1985
Plasma cortisol determination for the dexamethasone suppression test. Comparison of competitive protein-binding and commercial radioimmunoassay methodsJ C Ritchie, B J Carroll, P R Olton, et al.
Pageof 9